Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites

被引:54
作者
El-Kabbani, O.
Podjarny, A.
机构
[1] Monash Univ, Dept Med Chem, Victorian Coll Pharm, Parkville, Vic 3052, Australia
[2] ULP, Dept Struct Biol & Genom, IGBMC, INSERM,UMR 7104,CNRS, F-67404 Illkirch Graffenstaden, France
关键词
aldose reductase; aldehyde reductase; polyol pathway; glucose metabolism; enzyme inhibition; drug design; diabetes;
D O I
10.1007/s00018-007-6514-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aldose reductase and aldehyde reductase belong to the aldo-keto reductase superfamily of enzymes whose members are responsible for a wide variety of biological functions. Aldose reductase has been identified as the first enzyme involved in the polyol pathway of glucose metabolism which converts glucose into sorbitol. Glucose over-utilization through the polyol pathway has been linked to tissue-based pathologies associated with diabetes complications, which make the development of a potent aldose reductase inhibitor an obvious and attractive strategy to prevent or delay the onset and progression of the complications. Structural studies of aldose reductase and the homologous aldehyde reductase in complex with inhibitor were carried out to explain the difference in the potency of enzyme inhibition. The aim of this review is to provide a comprehensive summary of previous studies to aid the development of aldose reductase inhibitors that may have less toxicity problems than the currently available ones.
引用
收藏
页码:1970 / 1978
页数:9
相关论文
共 58 条
[1]  
Ashizawa Naoki, 1998, Drugs of the Future, V23, P521, DOI 10.1358/dof.1998.023.05.858358
[2]   The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity [J].
Barski, OA ;
Gabbay, KH ;
Bohren, KM .
BIOCHEMISTRY, 1996, 35 (45) :14276-14280
[3]   MECHANISM OF HUMAN ALDEHYDE REDUCTASE - CHARACTERIZATION OF THE ACTIVE-SITE POCKET [J].
BARSKI, OA ;
GABBAY, KH ;
GRIMSHAW, CE ;
BOHREN, KM .
BIOCHEMISTRY, 1995, 34 (35) :11264-11275
[4]  
BOHREN KM, 1992, J BIOL CHEM, V267, P20965
[5]   Pharmacological approaches to the treatment of diabetic complications [J].
Costantino, L ;
Rastelli, G ;
Gamberini, MC ;
Barlocco, D .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (08) :1245-1262
[6]   [1,2,4]triazino[4,3-a]benzimidazole acetic acid derivatives:: A new class of selective aldose reductase inhibitors [J].
Da Settimo, F ;
Primofiore, G ;
Da Settimo, A ;
La Motta, C ;
Taliani, S ;
Simorini, F ;
Novellino, E ;
Greco, G ;
Lavecchia, A ;
Boldrini, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (25) :4359-4369
[7]   Probing the ultra-high resolution structure of aldose reductase with molecular modelling and noncovalent mass spectrometry [J].
Darmanin, C ;
Chevreux, G ;
Potier, N ;
Van Dorsselaer, A ;
Hazemann, I ;
Podjarny, A ;
El-Kabbani, O .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (14) :3797-3806
[8]   Kinetic and structural characterization of the glutathione-binding site of aldose reductase [J].
Dixit, BL ;
Balendiran, GK ;
Watowich, SJ ;
Srivastava, S ;
Ramana, KV ;
Petrash, JM ;
Bhatnagar, A ;
Srivastava, SK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (28) :21587-21595
[9]   Aldose reductase and the role of the polyol pathway in diabetic nephropathy [J].
Dunlop, M .
KIDNEY INTERNATIONAL, 2000, 58 :S3-S12
[10]  
EGGLER JF, 1993, ADV MED CHEM, V2, P197